A Phase 1 interventional study of ONO-4538 in Advanced Solid Tumors and Recurrent Solid Tumors, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 5 sites in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.
Sponsored by Ono Pharmaceutical Co. Ltd · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate treatment is available.
Ono Pharmaceutical Co. Ltd is the lead sponsor of 63 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ONO-4538 water-soluble injection, 100 mg/vial, 1mg/kg, single dose
Drug: ONO-4538
ONO-4538 water-soluble injection, 100 mg/vial, 3mg/kg, single dose
Drug: ONO-4538
ONO-4538 water-soluble injection, 100 mg/vial, 10mg/kg, single dose
Drug: ONO-4538
PK Outcome: Cmax of ONO-4538
Cmax was the maximum serum concentration of ONO-4538 after the single administration.
Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
PK Outcome: Tmax of ONO-4538
Tmax was the time to reach the Cmax.
Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
AUC21day
AUC21day was the area under serum concentration-time curve of ONO-4538 from day 0 to day 21 (last measurement).
Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
AUCinf
AUCinf was the area under serum concentration-time curve of ONO-4538 extrapolated to infinity.
Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
T1/2
T1/2 was the elimination half-life of serum concentration of ONO-4538.
Time frame: 3 weeks: from the start of administration to the end of treatment phase. Actual blood sampling points are pre-dose, 1hr, 3hr, 9hr, 25hr, 49hr, 73hr, 169hr, 337hr, and 504hr.
Safety Outcome: The Number of Subjects With Overall Adverse Events
Adverse Events (AEs) were analyzed based on treatment emergent AEs (TEAEs), defined as any event not present prior to initiation of investigational product that first appeared following exposure to investigational product or any event already present that worsened relative to the pre-treatment state following exposure to investigational product.
Time frame: 3 weeks: from the start of administration to the end of treatment phase.
Safety Outcome: The Number of Deaths
Number of subjects with TEAEs leading to death.
Time frame: 3 weeks: from the start of administration to the end of treatment phase.
| Milestone | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| Started | 6 | 6 | 6 |
| Completed | 6 | 6 | 5 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Disease progression | 0 | 0 | 1 |
Cmax was the maximum serum concentration of ONO-4538 after the single administration.
| µg/mL | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| PK Outcome: Cmax of ONO-4538 | 26.0 ± 4.29 | 64.3 ± 22.5 | 242.0 ± 66.7 |
Tmax was the time to reach the Cmax.
| hours | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| PK Outcome: Tmax of ONO-4538 | 3.02 (1.07 to 9.00) | 3.00 (1.00 to 8.78) | 2.99 (1.00 to 8.62) |
AUC21day was the area under serum concentration-time curve of ONO-4538 from day 0 to day 21 (last measurement).
| µg*h/mL | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| AUC21day | 5110 ± 952 | 12200 ± 2060 | 38700 ± 14200 |
AUCinf was the area under serum concentration-time curve of ONO-4538 extrapolated to infinity.
| µg*h/mL | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| AUCinf | 9180 ± 3140 | 22800 ± 10000 | 68100 ± 34700 |
T1/2 was the elimination half-life of serum concentration of ONO-4538.
| days | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| T1/2 | 18.3 ± 6.97 | 19.1 ± 10.0 | 15.0 ± 7.86 |
Adverse Events (AEs) were analyzed based on treatment emergent AEs (TEAEs), defined as any event not present prior to initiation of investigational product that first appeared following exposure to investigational product or any event already present that worsened relative to the pre-treatment state following exposure to investigational product.
| participants | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| Safety Outcome: The Number of Subjects With Overall Adverse Events | 5 | 4 | 5 |
Number of subjects with TEAEs leading to death.
| Participants | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| Safety Outcome: The Number of Deaths | 1 | 0 | 1 |
Collected over 3 weeks: from the start of administration to the end of treatment phase.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ONO-4538 1 mg/kg | 1/6 (16.7%) | 1/6 (16.7%) | 5/6 (83.3%) |
| ONO-4538 3 mg/kg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| ONO-4538 10 mg/kg | 1/6 (16.7%) | 1/6 (16.7%) | 5/6 (83.3%) |
| Event | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| Blood bilirubin increasedInvestigations | 1/6 | 0/6 | 1/6 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/6 | 1/6 |
| Event | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/6 | 0/6 | 3/6 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 1/6 | 3/6 |
| PyrexiaGeneral disorders | 1/6 | 0/6 | 2/6 |
| Vertigo positionalEar and labyrinth disorders | 0/6 | 0/6 | 1/6 |
| HyperthyroidismEndocrine disorders | 1/6 | 0/6 | 0/6 |
| Autoimmune thyroiditisEndocrine disorders | 1/6 | 0/6 | 0/6 |
| Ulcerative keratitisEye disorders | 0/6 | 0/6 | 1/6 |
| AscitesGastrointestinal disorders | 1/6 | 0/6 | 0/6 |
| ConstipationGastrointestinal disorders | 0/6 | 0/6 | 1/6 |
| NauseaGastrointestinal disorders | 0/6 | 0/6 | 1/6 |
| Age, Continuous(years) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| Median | 44.5 (36 to 74) | 63.0 (49 to 70) | 52.5 (27 to 84) | 56.0 (27 to 84) |
| Age, Customized(Participants) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| <65 years | 4 | 3 | 4 | 11 |
| >=65-<75 years | 2 | 3 | 1 | 6 |
| >=75 years | 0 | 0 | 1 | 1 |
| Sex: Female, Male(Participants) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| Female | 5 | 1 | 4 | 10 |
| Male | 1 | 5 | 2 | 8 |
| Region of Enrollment(participants) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| South Korea | 6 | 6 | 6 | 18 |
| Height(Centimeter) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| Median | 156.60 (150.0 to 172.1) | 161.90 (151.0 to 173.0) | 161.35 (157.5 to 174.0) | 160.85 (150.0 to 174.0) |
| Weight(Kilogram) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| Median | 56.75 (48.2 to 78.5) | 63.40 (47.0 to 75.0) | 57.50 (49.8 to 68.2) | 59.25 (47.0 to 78.5) |
| BMI(Kilogram per square meter) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| Median | 22.62 (19.9 to 28.0) | 23.26 (18.9 to 32.9) | 21.55 (19.3 to 25.8) | 22.57 (18.9 to 32.9) |
| Performance status (Eastern Cooperative Oncology Group)(Participants) | ONO-4538 1 mg/kg | ONO-4538 3 mg/kg | ONO-4538 10 mg/kg | Total |
|---|---|---|---|---|
| PS 0 | 4 | 1 | 3 | 8 |
| PS 1 | 2 | 5 | 3 | 10 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2014 to primary completion in Dec 2014, 2 months.
Results were first posted in Apr 2024, 9 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nivolumab